Guidance updated on PSA testing for prostate cancer
We have published updated guidance for GPs and well men aged 50 and over about prostate specific antigen (PSA) testing for prostate cancer.
Elizabeth is Public Health England's Cervical Screening Programme Development Lead.
We have published updated guidance for GPs and well men aged 50 and over about prostate specific antigen (PSA) testing for prostate cancer.
Explanation to accompany a new cervical screening HPV primary report.
In 2013, 6 labs in England began looking for HPV first to see if this new test could be used in the cervical screening programme. The results from this pilot have now been published in the British Medical Journal (BMJ).
We have published new guidance for local cervical screening providers on implementing high-risk human papillomavirus (hrHPV) testing as the programme’s primary screening test.
Over the last few months we've been working hard to update and improve the existing cervical screening failsafe guidelines and screening services need to be aware of the updated requirements.
PHE has published guidance describing the role and responsibilities of cervical screening provider leads.
PHE Screening has published guidance for laboratories and local cervical screening providers to support the option of mitigating against the risk of longer cytology backlogs by using primary HPV screening pilot sites.
Cervical screening saves an estimated 5,000 lives a year by detecting abnormalities of the cervix early and referring women for effective treatment.
Public Health England (PHE) existed to protect and improve the nation’s health and wellbeing, and reduce health inequalities. It closed on 30 September 2021 and this blog is no longer updated.
Find out more about the implications for health screening in our Changes ahead for the national screening system blog article.
If you want to stay in touch with screening evidence and policy news, you can subscribe to the UK National Screening Committee blog.